Calian Group Ltd. · TSX:CGY
Calian — Q4 2022 Earnings Presentation
17 slides from Calian's earnings presentation, Nov 25, 2022
Slide 1: Investor Presentation – Q4 FY22
Investor Presentation – Q4 FY22 November 25, 2022
Slide 2: Caution Regarding Forward Looking Statements
Caution Regarding Forward Looking Statements Certain information included in this document is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events. Such statements are generally ac
Slide 3: Q4-22 Consolidated Results
Q4-22 Consolidated Results $161M $102M -11% 36% New Contract Signings Contract Renewals Organic Growth Acquisitive Growth Revenues Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $) (in millions of $, except margin) (in millions of $, except margin) 60 40.0% 150 161 20.0 19.1 50 22.0% 1
Slide 4: FY22 Consolidated Results
FY22 Consolidated Results $699M $1.3B -6% 19% New Contract Signings Backlog Organic Growth Acquisitive Growth Revenue & Organic Growth Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $, except %) (in millions of $, except margin) (in millions of $, except margin) 700 180 169 40.0% 70 66
Slide 5: Last 5 Years – Revenue Diversification
Last 5 Years – Revenue Diversification Geography Offering Customer 20% 19% 25% 22% 18% 20% 25% 27% 29% 33% 32% 31% 47% 49% 53% 80% 81% 75% 78% 82% 80% 75% 71% 67% 73% 68% 69% 53% 51% 47% 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 Canada International Service Product G
Slide 6: Q4-22 ITCS
Q4-22 ITCS $56M $97M 12% 185% New Contract Signings Backlog Organic Growth Acquisitive Growth Revenues Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $, except margin) (in millions of $, except margin) (in millions of $) 69 30 65.0% 14.0 35.0% 12.4 25.1 60.0% 25 12.0 49 55.0% 30.0% 19.
Slide 7: Q4-22 Health
Q4-22 Health $35M $707M -11% 0% New Contract Signings Backlog Organic Growth Acquisitive Growth Revenues Gross Profit & Margin Adj. EBITDA1 & Margin1 (in millions of $, except margin) (in millions of $, except margin) (in millions of $) 10.0 40.0% 35.0% 14.0 9.0 44 42 45 7.9 8.0 30.0% 40 12.0 11.1 1
Slide 8: Q4-22 Advanced Technologies
Q4-22 Advanced Technologies $60M $160M -31% 0% New Contract Signings Backlog Organic Growth Acquisitive Growth Gross Profit & Margin Adj. EBITDA1 & Margin1 Revenues (in millions of $, except margin) (in millions of $, except margin) (in millions of $) 45.0% 7.0 12 11.3 11.2 11.2 43 10.7 27.0% 41 40
Slide 9: Q4-22 Learning
Q4-22 Learning $10M $328M 8% 16% New Contract Signings Backlog Organic Growth Acquisitive Growth Gross Profit & Margin Adj. EBITDA1 & Margin1 Revenues (in millions of $, except margin) (in millions of $) (in millions of $, except margin) 8.0 6.0 40.0% 5.4 25 6.8 32.0% 23 7.0 5.0 22 22 5.7 5.9 35.0%
Slide 10: FY22 - Net Profit & Adj. Net Profit
FY22 - Net Profit & Adj. Net Profit Net Profit Adj. Net Profit1 Adj. EPS Diluted1 (in millions of $) (in millions of $) (in dollars) 44 $3.87 20 20 37 $3.50 16 14 $2.59 $2.41 11 24 19 5 $0.60 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 1) This is a non-GAAP measure. Pl
Slide 11: FY22 - Cash Flow & Operating FCF Generation
FY22 - Cash Flow & Operating FCF Generation Adj. EBITDA1 Operating Free Cash Flow (OFCF)1&2 OFCF Conversion1&2 (in millions of $) (in millions of $) (in %) 70 66 76% 47 72% 60 66% 52 63% 50 34 51% 40 37 28 30 25 27 17 13 20 10 0 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2
Slide 12: FY22 – Capital Deployment
FY22 – Capital Deployment Acquisitions Dividends Capex1 (in millions of $) (in millions of $) (in millions of $) 13 66 12 8 7 10 7 49 9 9 6 5 29 21 5 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 1) Capex = Equipment and application software + Capitalized R&D Capital dep
Slide 13: FY22 - Balance Sheet
FY22- Balance Sheet Total Debt Cash & Cash Equivalents Net Liquidity (in millions of $) (in millions of $) (in millions of $) 79 159 13 115 8 43 84 62 24 22 44 17 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 1) Net Liquidity= Unused portion of credit line + cash & cash
Slide 14: FY22 – Backlog & New Contract Signings
FY22 – Backlog & New Contract Signings Backlog New Contract Signings R&D Investments1 (in billions of $) (in millions of $) (in millions of $) 699 5.9 1.33 1.29 5.5 5.5 1.31 1.27 1.23 492 442 447 3.2 3.2 270 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 2018 2019 2020 2021 2022 1) R&D investment
Slide 15: FY23 - Guidance
FY23 - Guidance Revenues Adj. EBITDA1 Adj. Net Profit1 (in millions of $) (in millions of $) (in millions of $) 630-680 70-75 46-50 582 518 66 44 432 52 37 343 37 24 27 19 2019 2020 2021 2022 2023E 2019 2020 2021 2022 2023E 2019 2020 2021 2022 2023E 1) This is a non-GAAP measure. Please refer to the
Slide 16: Published Inaugural ESG Report
Published Inaugural ESG Report
Slide 17: Thank you
—— CALIAN . Thank you ir@calian.com